Skip to main content
. 2020 Nov 11;16:97. doi: 10.1186/s13223-020-00496-0

Table 3.

Active treatment at enrolment in the study population

Variable Population cohort (n = 61)
Treatment
Non-sedative H1-antihistamines 100% (n = 61)
Number of daily doses
 4 14.8% (n = 9)
 3 13.1% (n = 8)
 2 52.4% (n = 32)
 1 19.7% (n = 12)
Montelukast
 Yes 13.1% (n = 8)
Omalizumab
 Yes 6.6% (n = 4)
Systemic corticotherapy
 Yes 6.6% (n = 4)
Ciclosporine
 Yes 1.6% (n = 1)